Alfredo Páez-Carpio1, Santiago Medrano-Martorell2, Joan Berenguer2, Africa Muxí3, Isabel Vilaseca4, Izaskun Valduvieco5, Paola Castillo6, Neus Baste7, F Xavier Avilés-Jurado4, Juan José Grau7, Laura Oleaga2. 1. Department of Radiology, CDI, Hospital Clínic Barcelona, Barcelona, Spain. paez@clinic.cat. 2. Department of Radiology, CDI, Hospital Clínic Barcelona, Barcelona, Spain. 3. Department of Nuclear Medicine, CDI, Hospital Clínic Barcelona, Barcelona, Spain. 4. Otorhinolaryngology Service, Hospital Clínic Barcelona, Barcelona, Spain. 5. Radiotherapy Oncology Service, ICMHO, Hospital Clínic Barcelona, Barcelona, Spain. 6. Pathology Service, CDB, Hospital Clínic Barcelona, Barcelona, Spain. 7. Medical Oncology Service, ICMHO, Hospital Clínic Barcelona, Barcelona, Spain.
Abstract
PURPOSE: To identify response predictors in patients with head and neck squamous cell carcinoma (N + HNSCC) and persistent lymph nodes after curative chemoradiotherapy treatment (CCRT). MATERIALS AND METHODS: Consecutive patients with N + HNSCC treated with CCRT and persistent lymph nodes at first follow-up between 2015 and 2021 were identified and analyzed. Complete response was defined as the absence of lymph node metastatic involvement in patients with salvage lymphadenectomy or the absence of progression after 1 year of successive follow-ups. Tumour type and location, staging, and human papillomavirus (HPV) status were considered for analysis. The number and size of lymph nodes, type, shape, enhancement and margins on diagnostic and follow-up CT were also analyzed. RESULTS: The cohort included 46 patients with 134 pathological lymph nodes. Logistic regression models showed the following variables to be significant: performance of salvage lymphadenectomy (OR 0.094, [CI 95% 0.004-0.61], p = 0.037); the type of lymphadenopathy on diagnostic CE-CT (solid vs. cystic) (N1: OR = 4.11, [CI 95% 1.11-17.93], p = 0.042 and N3: OR 6.42, [CI 95% 1.2-42.56], p = 0.036); the change of shape (round to oval) on the follow-up CE-CT (OR 9.76, [CI 95% 1.79-8.57], p = 0.016) and the time in days between CCRT and the first follow-up CE-CT (OR 1.06, [CI 95% 1.004-1.13], p = 0.048). CONCLUSIONS: In our experience, the presence of solid lymph nodes on pre-treatment CT and the change in shape from round to oval on post-treatment CT are predictors of response to treatment in patients with N + HNSCC persistent lymph nodes after CCRT. Increasing the temporal interval between treatment and follow-up CT should be considered to avoid unnecessary nodal dissections.
PURPOSE: To identify response predictors in patients with head and neck squamous cell carcinoma (N + HNSCC) and persistent lymph nodes after curative chemoradiotherapy treatment (CCRT). MATERIALS AND METHODS: Consecutive patients with N + HNSCC treated with CCRT and persistent lymph nodes at first follow-up between 2015 and 2021 were identified and analyzed. Complete response was defined as the absence of lymph node metastatic involvement in patients with salvage lymphadenectomy or the absence of progression after 1 year of successive follow-ups. Tumour type and location, staging, and human papillomavirus (HPV) status were considered for analysis. The number and size of lymph nodes, type, shape, enhancement and margins on diagnostic and follow-up CT were also analyzed. RESULTS: The cohort included 46 patients with 134 pathological lymph nodes. Logistic regression models showed the following variables to be significant: performance of salvage lymphadenectomy (OR 0.094, [CI 95% 0.004-0.61], p = 0.037); the type of lymphadenopathy on diagnostic CE-CT (solid vs. cystic) (N1: OR = 4.11, [CI 95% 1.11-17.93], p = 0.042 and N3: OR 6.42, [CI 95% 1.2-42.56], p = 0.036); the change of shape (round to oval) on the follow-up CE-CT (OR 9.76, [CI 95% 1.79-8.57], p = 0.016) and the time in days between CCRT and the first follow-up CE-CT (OR 1.06, [CI 95% 1.004-1.13], p = 0.048). CONCLUSIONS: In our experience, the presence of solid lymph nodes on pre-treatment CT and the change in shape from round to oval on post-treatment CT are predictors of response to treatment in patients with N + HNSCC persistent lymph nodes after CCRT. Increasing the temporal interval between treatment and follow-up CT should be considered to avoid unnecessary nodal dissections.
Authors: Juliette Thariat; K Kian Ang; Pamela K Allen; Anesa Ahamad; Michelle D Williams; Jeffrey N Myers; Adel K El-Naggar; Lawrence E Ginsberg; David I Rosenthal; Bonnie S Glisson; William H Morrison; Randal S Weber; Adam S Garden Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-01 Impact factor: 7.038
Authors: Anuj Goenka; Luc G T Morris; Shyam S Rao; Suzanne L Wolden; Richard J Wong; Dennis H Kraus; Nisha Ohri; Jeremy Setton; Benjamin H Lok; Nadeem Riaz; Borys R Mychalczak; Heiko Schoder; Ian Ganly; Jatin P Shah; David G Pfister; Michael J Zelefsky; Nancy Y Lee Journal: Int J Cancer Date: 2013-03-29 Impact factor: 7.396
Authors: T S Boyd; P M Harari; S P Tannehill; M C Voytovich; G K Hartig; C N Ford; R L Foote; B H Campbell; C J Schultz Journal: Head Neck Date: 1998-03 Impact factor: 3.147
Authors: Karlijn van den Bovenkamp; Bart Dorgelo; Maartje G Noordhuis; Bernard F A M van der Laan; Bert van der Vegt; Hendrik P Bijl; Jan L Roodenburg; Boukje A C van Dijk; Sjoukje F Oosting; Ed M D Schuuring; Johannes A Langendijk; Gyorgy B Halmos; Boudewijn E C Plaat Journal: Oral Oncol Date: 2018-01-08 Impact factor: 5.337
Authors: Stanley L Liauw; Anthony A Mancuso; Robert J Amdur; Christopher G Morris; Douglas B Villaret; John W Werning; William M Mendenhall Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Lars Schüttrumpf; Sebastian Marschner; Katrin Scheu; Julia Hess; Sibylle Rietzler; Axel Walch; Philipp Baumeister; Thomas Kirchner; Ute Ganswindt; Horst Zitzelsberger; Claus Belka; Cornelius Maihoefer Journal: Radiat Oncol Date: 2020-01-06 Impact factor: 3.481